SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

KPI-014

KALA·KALA BIO, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Not stated
Time to market
Not stated
Why 2/10
KPI-014 is a preclinical-stage candidate for inherited retinal degenerative diseases (retinitis pigmentosa, Stargardt disease). No clinical trials have been initiated, no IND filing has been announced, and no hard, dated catalyst exists in the next ~12 months. The company is pivoting to an AI infrastructure platform and has minimal cash ($7.0M), making advancement of this program highly uncertain.
Actionable Insight NEUTRAL

KPI-014 is an early preclinical program at a company that recently suffered a clinical failure (KPI-012 Phase 2b miss in September 2025), has a market cap around $3M, and is pivoting to an AI platform business model. Watch for any mention of KPI-014 in future corporate updates, but the program appears dormant or deprioritized given the company's financial constraints and strategic shift.

Price Chart

Loading chart...

Executive Summary

KPI-014 is a preclinical candidate from KALA BIO's mesenchymal stem cell secretome (MSC-S) platform, being explored for inherited retinal degenerative diseases such as retinitis pigmentosa and Stargardt disease. The program was first disclosed in 2024 as an early-stage research initiative. As of November 2026, no clinical trials have been registered, no IND has been announced, and no near-term catalyst is scheduled. KALA BIO's stock trades around $0.17 with a market cap of roughly $3 million, following an 88% crash in October 2025 after its lead clinical candidate KPI-012 failed a Phase 2b study. The company reported a preliminary Q3 2026 net loss of $0.8M with $7.0M cash and no debt, and announced a strategic pivot to an AI infrastructure platform for biotech. KPI-014 appears to be a very early, likely deprioritized program with no imminent value-driving catalyst.

The Two-Sided Case

▲ Bull Case3
KPI-014 targets inherited retinal degenerative diseases (retinitis pigmentosa, Stargardt disease), areas with significant unmet need and no approved therapies for many patients.
The MSC-S platform is a novel biologic approach that could differentiate from gene therapy competitors if preclinical data prove promising.
KALA BIO has dramatically reduced its cash burn (Q3 2026 net loss of ~$0.8M vs $7.6M in Q3 2025), extending its runway to potentially advance early-stage programs.
▼ Bear Case5
KPI-014 is preclinical only with no clinical trials initiated, no IND filed, and no hard catalyst in the next ~12 months.
KALA BIO's lead candidate KPI-012 failed its Phase 2b CHASE study in September 2025, causing an 88% stock crash and raising questions about the MSC-S platform's therapeutic potential.
The company is pivoting to an AI infrastructure platform business model, suggesting KPI-014 and the broader biologics pipeline may be deprioritized.
With only $7.0M cash and a ~$3M market cap, KALA BIO has very limited resources to fund preclinical development and IND-enabling studies for KPI-014.
Analyst consensus is bearish: 0 buy, 3 hold, 1 sell, 2 strong sell ratings.

Upcoming Catalysts

  • No hard, dated catalyst is scheduled for KPI-014 in the next ~12 months.
  • KALA BIO's Q3 2026 10-Q filing is expected on or about November 16, 2026, which may provide an update on pipeline priorities.
  • The company's strategic pivot to an AI platform may result in further de-emphasis of the biologics pipeline including KPI-014.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

KALA BIO, Inc. 8-K KALA ·Originating report

Sources · 3

Hover a chip for the title
1 insidermonkey.com2 markets.financialcontent.com3 nasdaq.com